Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Mesothelioma, Malignant 1Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 53pembrolizumab 51Carboplatin 51Magnetic Resonance Spectroscopy 46Pemetrexed 41Cisplatin 36Paclitaxel 25durvalumab 24osimertinib 22Nivolumab 22Gemcitabine 20Radiosurgery 18Radiotherapy 17Docetaxel 17atezolizumab 15Immunoglobulin G 15Biopsy 15Disulfides 14130-nm albumin-bound paclitaxel 13Taxes 12Radiation 12Educational Status 12Etoposide 11Blood Specimen Collection 11Early Intervention, Educational 10Drug Therapy 10Practice Guidelines as Topic 9Platinum 9Methods 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × methoxyamine × 90 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡